Sep 04, 2020 The US Food and Drug Administration has issued a warning letter to Mylan Laboratories Limited's plant in Telangana for significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). USFDA in their letter dated…
Recent Post
- Loan Licensing in Pharmaceutical Manufacturing: Key Principles, Guidelines, and Regulatory Framework
- Safe Handling of Narcotic and Psychotropic Drugs in a Wholesale Warehouse: A Complete Guide
- Understanding the Requirements for a Validation Master Plan (VMP) as per Regulatory Agencies: USFDA, EU GMP, MHRA, and PIC/S
- Complete Procedure to Meet CDSCO License Mandate of Class C & D Non-Notified Medical Devices
- Complete list of approved FDC